Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/2/2025

Pentoxifylline Use in Patients with Chronic Kidney Disease

Introduction to Pentoxifylline

  • Pentoxifylline is not recommended as a primary treatment for critical limb ischemia according to the American College of Cardiology/American Heart Association guidelines (Level of Evidence: B) 1
  • The American College of Cardiology/American Heart Association guidelines specifically state that parenteral administration of pentoxifylline is not useful for the treatment of critical limb ischemia (Level of Evidence: B) 1

Guideline Recommendations for CKD Stage 3

  • The Kidney Disease: Improving Global Outcomes and American College of Physicians guidelines recommend RAAS inhibition (ACE inhibitors or ARBs) as first-line therapy for patients with hypertension and CKD stage 3 2, 3
  • The American College of Physicians guidelines recommend statin therapy for lipid management in patients with CKD stage 3 3
  • For patients with diabetes and CKD stage 3, the Kidney Disease: Improving Global Outcomes guidelines recommend SGLT2 inhibitors and metformin (when eGFR ≥30 ml/min per 1.73 m²) 2

Management of Peripheral Vascular Disease in CKD Stage 3

  • For peripheral vascular disease in CKD stage 3, alternative therapies should be considered as pentoxifylline has limited evidence for efficacy, according to the American College of Cardiology/American Heart Association guidelines 1

Management of Proteinuria in CKD Stage 3

  • Ensure patient is already on optimal RAAS blockade (ACE inhibitor or ARB) before considering adding pentoxifylline for proteinuria management, as recommended by the American College of Physicians guidelines 3